A New Dry Eye Drug MIEBO™ Approved by FDA, Heng Rui Pharmaceutical Holds Chinese Rights

In May 2024 MIEBO™ (perfluorohexyloctane ophthalmic solution; formerly known as NOV03) was approved for the treatment of the signs and symptoms of dry eye disease (DED) in the USA. MIEBO™ is the first and only FDA-approved treatment for DED that directly targets tear evaporation. According to public information, Heng Rui Pharmaceutical holds exclusive rights to the drug in China and has already submitted the drug’s marketing application in China.

According to public information, the newly approved MIEBO™ is colorless and transparent, consisting of 100% perfluorohexyloctane. The eye drops rapidly spread across the entire ocular surface and interact with the lipid layer of the tear film, covering the surface of the aqueous layer of the tear film. This stabilizes the tear film and prevents excessive tear evaporation. Additionally, the eye drops can penetrate the meibomian glands, interact with the glands, and dissolve the viscous secretions within the glands, thus treating evaporative dry eye disease associated with meibomian gland dysfunction.